Biotech Specialty Pharma

Northwest Biotherapeutics Inc

7600 Wisconsin Ave, Suite 750
Bethesda, MD 20814 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Immunotherapy products for cancer treatment

Management Linda F. Powers, Chief Executive Officer; Alton L. Boynton, Ph.D., Chief Scientific Officer; Anthony Maida, Ph.D., Chief Operating Officer; Les Goldman, Senior Vice President, Business Development; Marnix L. Bosch, Ph.D., Chief Technical Officer

Click here for Financial Data
Keywords: oncology, brain, Urology, prostate, urinary, bladder, erectile, cancer, mouse cell, immunotherapy


Updated: Jun. 19, 2019


Northwest Biotherapeutics Inc. is developing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company's approach to developing therapies lies in its expert......view more

Products / Services

DCVax-Brain HuRx-Prostate......view more

Technology / Differentiation

DCVax is a dendritic cell-based cancer immunotherapy platform. DCVax therapies are designed to safely elicit potent immune responses that eliminate cancer cells. HuRx is a monoclonal antibody-base...view more

Market / Customers

Currently approved cancer treatments are frequently ineffective and can cause undesirable side effects.......view more


DCVax-Brain, has been granted an Orphan Drug designation and received clearance from the FDA, to commence a Phase II clinical trial for glioblastoma, a lethal form of brain cancer. This trial is curre...view more